IP Library Granted Patent US 11,860,158
Granted Patent B2
US 11,860,158 · App. 16/282,558 · Granted Jan 2, 2024

Unmasking endotoxins in solution

Inventors: Johannes Reich (Weilheim, DE); Holger Grallert (Weilheim, DE)
Assignee: BIOMÉRIEUX DEUTSCHLAND GMBH
G01N33/5306G01N33/50G01N33/92G01N2400/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,860,158
App. No.
16/282,558
Granted
Jan 2, 2024
Kind
B2
Abstract

The invention relates to unmasking endotoxins in compositions so that previously present, but undetectable endotoxins are rendered detectable.

Claims (15)

1. A kit for use in unmasking an endotoxin in a composition, the kit comprising:

a) a saturated unbranched 1-alkanol comprising 8 to 16 carbon atoms that is 1-dodecanol;

b) sodium dodecyl sulfate (SDS) and/or an albumin;

c) a divalent cation selected from the group consisting of Ca 2+ , Mg 2+ , Sr 2+ and Zn 2+ ; and

wherein components a), b), and c) are in same or different packages, the kit further comprising a known amount, concentration or units of a lipopolysaccharide (LPS) endotoxin positive control containing non-masked LPS, the positive control being positioned in a separate container.

2. The kit according to claim 1 , wherein said kit additionally comprises one or both of the following: instructions for unmasking an endotoxin in a composition and instructions for detecting an endotoxin in a composition.

3. The kit according to claim 1 , wherein element b) is an albumin.

4. The kit according to claim 1 , wherein element b) is SDS.

5. The kit according to claim 3 , wherein said albumin is human serum albumin, bovine serum albumin (BSA) and/or ovalbumin.

6. The kit according to claim 1 , wherein element c) is Ca 2+ .

7. The kit according to claim 1 , further comprising a chaotropic agent.

8. The kit according to claim 7 , wherein the chaotropic agent is selected from the group consisting of urea; guanidinium chloride; butanol; ethanol; lithium perchlorate; lithium acetate; magnesium chloride; phenol; propanol; and thiourea.

9. The kit according to claim 1 , wherein the amount of LPS in the separate container is known.

10. The kit according to claim 1 , wherein the concentration of LPS in the separate container is known.

11. The kit according to claim 1 , wherein the units of LPS in the separate container are known.

Assignments (1)
MERGER Recorded Mar 12, 2021
From: HYGLOS INVEST GMBH
To: BIOMÉRIEUX DEUTSCHLAND GMBH
Reel/Frame 055574/0709 →
Priority Claims (1)
EP 14172151 · Jun 12, 2014 · regional
Continuity (3)
Division 15318086
Provisional Application 62011818 · Jun 13, 2014
Related Publication 20190187131A1 · Jun 20, 2019